Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calaspargase Pegol vs Pegaspargase in High-Risk ALL
NCT00671034Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Jul 2008
- Primary completion
- Feb 2011
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of calaspargase pegol in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Pharmacokinetics (Half-life of SC-PEG E. Coli L-asparaginase). Started Jul 2008; status: completed.
02
Drugs
calaspargase pegol
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00671034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00671034.